LBPH vs. AADI, PBYI, IFRX, BIVI, ANNX, XBIT, ALT, DBTX, SBTX, and DSGN
Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Aadi Bioscience (AADI), Puma Biotechnology (PBYI), InflaRx (IFRX), BioVie (BIVI), Annexon (ANNX), XBiotech (XBIT), Altimmune (ALT), Decibel Therapeutics (DBTX), Silverback Therapeutics (SBTX), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical preparations" industry.
Longboard Pharmaceuticals (NASDAQ:LBPH) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability.
63.3% of Longboard Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.3% of Aadi Bioscience shares are owned by institutional investors. 5.6% of Longboard Pharmaceuticals shares are owned by company insiders. Comparatively, 35.8% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Longboard Pharmaceuticals presently has a consensus price target of $17.40, indicating a potential upside of 213.51%. Aadi Bioscience has a consensus price target of $39.00, indicating a potential upside of 647.13%. Given Aadi Bioscience's higher probable upside, analysts plainly believe Aadi Bioscience is more favorable than Longboard Pharmaceuticals.
Longboard Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
In the previous week, Longboard Pharmaceuticals and Longboard Pharmaceuticals both had 2 articles in the media. Longboard Pharmaceuticals' average media sentiment score of 1.44 beat Aadi Bioscience's score of 0.42 indicating that Longboard Pharmaceuticals is being referred to more favorably in the media.
Longboard Pharmaceuticals received 18 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 62.79% of users gave Longboard Pharmaceuticals an outperform vote while only 47.37% of users gave Aadi Bioscience an outperform vote.
Longboard Pharmaceuticals has higher earnings, but lower revenue than Aadi Bioscience. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Longboard Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -285.87%. Aadi Bioscience's return on equity of -40.72% beat Longboard Pharmaceuticals' return on equity.
Summary
Longboard Pharmaceuticals beats Aadi Bioscience on 8 of the 15 factors compared between the two stocks.
Get Longboard Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longboard Pharmaceuticals Competitors List
Related Companies and Tools
